Pulse Biosciences Grants Equity Incentive Awards to New Employees
22 March 2018 - 7:00AM
Business Wire
Pulse Biosciences, Inc. (NASDAQ: PLSE), a medical technology
company developing a proprietary therapeutic tissue treatment based
on its Nano-Pulse Stimulation (NPS) platform, today announced that
the Compensation Committee of the company’s Board of Directors
granted non-qualified stock options covering an aggregate of 50,000
shares of Pulse Biosciences common stock to five new employees
under the Pulse Biosciences 2017 Inducement Equity Incentive Plan
on March 19, 2018.
The 2017 Inducement Equity Incentive Plan is used exclusively to
grant equity awards to individuals who were not previously an
employee or non-employee director of Pulse Biosciences as an
inducement material to such individual's entering into employment
with Pulse Biosciences in accordance with Nasdaq Marketplace Rule
5635(c)(4).
The options have an exercise price of $14.52 per share, which is
equal to the closing price of Pulse Biosciences common stock on
March 19, 2018. Each option will vest and become exercisable as to
25% of the shares on the first anniversary of the recipient’s start
date, and will vest and become exercisable as to the remaining 75%
of the shares in 36 equal monthly installments following the first
anniversary of the recipient’s start date, subject to each such
employee’s continued employment with Pulse Biosciences on these
vesting dates. The options are subject to the terms and conditions
of the 2017 Inducement Equity Incentive Plan and the award
agreements entered into with each recipient.
About Pulse Biosciences
Pulse Biosciences is a clinical stage electroceutical, an
electrical energy based therapeutic, company pursuing commercial
applications of its proprietary Nano-Pulse Stimulation (NPS)
technology. NPS is a non-thermal, precise, focal, drug-free tissue
treatment technology utilizing nanosecond (billionth of a second)
range pulsed electric fields that directly affect the cell membrane
and intracellular structures and initiates programmed cell death in
treated cells. The unique ability of NPS to initiate cell death has
the potential to significantly benefit patients in a wide variety
of medical applications including applications in immuno-oncology
and dermatology, and other potential applications we may pursue in
the future. The initiation of programmed cell death by NPS results
in a minimal inflammatory response, which improves healing outcomes
and supports the replacement of treated tissue cells with healthy
tissue cells. In cancerous lesions, NPS has been shown in
preclinical models to induce immunogenic cell death (ICD), which
exposes the unique antigens of the treated cells to the immune
system and enrolls immune system cells, such as cytotoxic T-cells
to mount an adaptive immune response. Pulse Biosciences is
investigating a variety of applications for its technology that
exploits the technology’s unique biologic effect, including
immuno-oncology and dermatology. More information is available at
www.pulsebiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180321006078/en/
Pulse Biosciences, Inc.Investors:Brian DowSr. Vice
President and Chief Financial OfficerIR@pulsebiosciences.comorThe
Trout GroupMike Zanoni,
646-378-2924mzanoni@troutgroup.comorMedia:Sam Brown, Inc.Christy
Curran, 615-414-8668christycurran@sambrown.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2024 to May 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From May 2023 to May 2024